Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2020 1
2021 2
2022 1
2023 1
2024 2
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Antoniotti C, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, Boquet I, Tamberi S, Marmorino F, Moretto R, Ambrosini M, Tamburini E, Tortora G, Passardi A, Bergamo F, Kassambara A, Sbarrato T, Morano F, Ritorto G, Borelli B, Boccaccino A, Conca V, Giordano M, Ugolini C, Fieschi J, Papadopulos A, Massoué C, Aprile G, Antonuzzo L, Gelsomino F, Martinelli E, Pella N, Masi G, Fontanini G, Boni L, Galon J, Cremolini C; GONO Foundation Investigators. Antoniotti C, et al. Lancet Oncol. 2022 Jul;23(7):876-887. doi: 10.1016/S1470-2045(22)00274-1. Epub 2022 May 27. Lancet Oncol. 2022. PMID: 35636444 Clinical Trial.
FUNDING: GONO Foundation, ARCO Foundation, F Hoffmann-La Roche, and Roche....
FUNDING: GONO Foundation, ARCO Foundation, F Hoffmann-La Roche, and Roche....
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, Medina L, Shacham-Shmueli E, Cosman R, Falcon A, Gort E, Guren T, Massarelli E, Miller WH Jr, Paz-Ares L, Prenen H, Amatu A, Cremolini C, Kim TW, Moreno V, Ou SI, Passardi A, Sacher A, Santoro A, Stec R, Ulahannan S, Arbour K, Lorusso P, Luo J, Patel MR, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Jun T, Dharia NV, Schutzman JL; GO42144 Investigator and Study Group; Han SW. Desai J, et al. Nat Med. 2024 Jan;30(1):271-278. doi: 10.1038/s41591-023-02696-8. Epub 2023 Dec 5. Nat Med. 2024. PMID: 38052910 Free PMC article. Clinical Trial.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Cremolini C, et al. Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. Lancet Oncol. 2020. PMID: 32164906 Free article. Clinical Trial.
FUNDING: The GONO Cooperative Group, the ARCO Foundation, and F Hoffmann-La Roche....
FUNDING: The GONO Cooperative Group, the ARCO Foundation, and F Hoffmann-La Roche....
PeroxiBase: the peroxidase database.
Passardi F, Theiler G, Zamocky M, Cosio C, Rouhier N, Teixera F, Margis-Pinheiro M, Ioannidis V, Penel C, Falquet L, Dunand C. Passardi F, et al. Phytochemistry. 2007 Jun;68(12):1605-11. doi: 10.1016/j.phytochem.2007.04.005. Epub 2007 Jun 4. Phytochemistry. 2007. PMID: 17544465
PeroxiBase was originally created for the exhaustive collection of class III peroxidase sequences from plants (Bakalovic, N., Passardi, F., et al., 2006. PeroxiBase: a class III plant peroxidase database. Phytochemistry 67, 534-539). ...
PeroxiBase was originally created for the exhaustive collection of class III peroxidase sequences from plants (Bakalovic, N., Passardi …
Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden.
Provenzano L, Gwee YX, Conca V, Lonardi S, Bozzarelli S, Tamburini E, Passardi A, Zaniboni A, Tosi F, Aprile G, Nasca V, Boccaccino A, Ambrosini M, Vetere G, Carullo M, Guaglio M, Battaglia L, Zhao JJ, Chia DKA, Yong WP, Tan P, So J, Kim G, Shabbir A, Ong CJ, Casella F, Cremolini C, Bencivenga M, Sundar R, Pietrantonio F. Provenzano L, et al. Ther Adv Med Oncol. 2024 Nov 4;16:17588359241289517. doi: 10.1177/17588359241289517. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39502404 Free PMC article.
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies.
Moretto R, Rossini D, Polito MG, Antoniotti C, Intini R, Conca V, Andena P, Carullo M, Salvatore L, Germani MM, Bergamo F, Passardi A, Ciracì P, Tamburini E, Boccaccio C, Zaniboni A, Masi G, Pietrantonio F, Lonardi S, Cremolini C. Moretto R, et al. Eur J Cancer. 2025 Jun 3;222:115470. doi: 10.1016/j.ejca.2025.115470. Epub 2025 Apr 26. Eur J Cancer. 2025. PMID: 40306121 Clinical Trial.
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study.
Moretto R, Giordano M, Poma AM, Passardi A, Boccaccino A, Pietrantonio F, Tomasello G, Aprile G, Lonardi S, Conca V, Granetto C, Frassoldati A, Clavarezza M, Bertolini AS, Germani MM, Ugolini C, Fontanini G, Masi G, Falcone A, Cremolini C. Moretto R, et al. Eur J Cancer. 2021 Aug;153:16-26. doi: 10.1016/j.ejca.2021.04.039. Epub 2021 Jun 12. Eur J Cancer. 2021. PMID: 34126333
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
Antoniotti C, Korn WM, Marmorino F, Rossini D, Lonardi S, Masi G, Randon G, Conca V, Boccaccino A, Tomasello G, Passardi A, Swensen J, Ugolini C, Oberley M, Tamburini E, Casagrande M, Domenyuk V, Fontanini G, Giordano M, Abraham J, Spetzler D, Falcone A, Lenz HJ, Cremolini C. Antoniotti C, et al. Eur J Cancer. 2021 Sep;155:73-84. doi: 10.1016/j.ejca.2021.06.037. Epub 2021 Aug 5. Eur J Cancer. 2021. PMID: 34365081
Reversible, PET-positive, generalized lymphadenopathy and splenomegaly during high-dose interferon-alpha-2b adjuvant therapy for melanoma.
Ridolfi L, Cangini D, Galassi R, Passardi A, Marzullo A, Moretti A, Framarini M, Tauceri F, Serra L, Chiarion-Sileni V, Ridolfi R. Ridolfi L, et al. J Immunother. 2008 Sep;31(7):675-8. doi: 10.1097/CJI.0b013e3181824d79. J Immunother. 2008. PMID: 18600177
The total body positron emission tomography showed a high F-fluorodeoxyglucose uptake (standardized uptake values >9), indicating possible lymph node and spleen malignancies. ...
The total body positron emission tomography showed a high F-fluorodeoxyglucose uptake (standardized uptake values >9), indicating …